Tags

Type your tag names separated by a space and hit enter

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
Mov Disord. 2008 Apr 30; 23(6):850-7.MD

Abstract

Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo- controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.

Authors+Show Affiliations

Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France. d-devos@chru-lille.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18311826

Citation

Devos, David, et al. "Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease: a Double-blind, Randomized, Placebo-controlled Study." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 23, no. 6, 2008, pp. 850-7.
Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23(6):850-7.
Devos, D., Dujardin, K., Poirot, I., Moreau, C., Cottencin, O., Thomas, P., Destée, A., Bordet, R., & Defebvre, L. (2008). Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society, 23(6), 850-7. https://doi.org/10.1002/mds.21966
Devos D, et al. Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease: a Double-blind, Randomized, Placebo-controlled Study. Mov Disord. 2008 Apr 30;23(6):850-7. PubMed PMID: 18311826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. AU - Devos,David, AU - Dujardin,Kathy, AU - Poirot,Isabelle, AU - Moreau,Caroline, AU - Cottencin,Olivier, AU - Thomas,Pierre, AU - Destée,Alain, AU - Bordet,Regis, AU - Defebvre,Luc, PY - 2008/3/4/pubmed PY - 2008/8/7/medline PY - 2008/3/4/entrez SP - 850 EP - 7 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 23 IS - 6 N2 - Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo- controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/18311826/Comparison_of_desipramine_and_citalopram_treatments_for_depression_in_Parkinson's_disease:_a_double_blind_randomized_placebo_controlled_study_ L2 - https://doi.org/10.1002/mds.21966 DB - PRIME DP - Unbound Medicine ER -